title: [The effect of fibrinolytic therapy for proliferative diabetic retinopathy complications on the angiogenic potential of the eye].
abstract: OBJECTIVE
  To investigate dynamic changes of pathogenically significant factors of tear fluid in type 2 diabetes patients with hemorrhagic proliferative diabetic retinopathy.
  
  
  METHODS
  A total of 30 patients (30 eyes) with type 2 diabetes mellitus and proliferative diabetic retinopathy complicated by preretinal and vitreous hemorrhages were assessed and treated with recombinant prourokinase (Gemaza). Levels of VEGF A, MCP-1, MMP-2, and MMP-9 in tear fluid were also measured.
  
  
  RESULTS
  Intravitreal injections of recombinant prourokinase led to more considerable gain of visual acuity and decrease of vitreous hemorrhage index in the first 24 hours in comparison with other treatment schemes. Changes of VEGF A and MCP-1 tear levels were insignificant. Increase of matrix proteinases activity was mainly due to MMP-9.
  
  
  CONCLUSIONS
  The use of recombinant prourokinase is associated with clinical improvement in patients with hemorrhagic diabetic retinopathy causing no notable changes in tear levels of proangiogenic cytokines and matrix proteinases.
authors.forename: I V
authors.initials: IV
authors.lastname: Vorob'eva
authors.forename: D A
authors.initials: DA
authors.lastname: Merkushenkova
authors.forename: E V
authors.initials: EV
authors.lastname: Parfenova
authors.forename: P A
authors.initials: PA
authors.lastname: Makarevich
mesh_terms: D003930:Diabetic Retinopathy / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004792:Enzyme Precursors; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009887:Ophthalmoscopy; D011994:Recombinant Proteins / Q000008:administration & dosage; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D015912:Thrombolytic Therapy / Q000379:methods*; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
chemical_list: D004792:Enzyme Precursors; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase